PRD Therapeutics
Innovative lipid metabolism regulators targeting rare diseases like HoFH and NASH.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | JPY1.3b | Series A | |
| Total Funding | 000k | ||
PRD Therapeutics is a pioneering drug discovery startup focused on developing innovative treatments for rare diseases related to lipid metabolism, such as Homozygous Familial Hypercholesterolemia (HoFH) and Nonalcoholic Steatohepatitis (NASH). The company operates in the biopharmaceutical market, which involves creating new medications to address unmet medical needs.
PRD Therapeutics' flagship product, PRD001, is a first-in-class lipid metabolism regulator. This means it is the first drug of its kind to target lipid metabolism in a unique way. Specifically, PRD001 is an oral medication that acts as a SOAT2 selective inhibitor, a type of drug that blocks a specific enzyme involved in lipid metabolism. By doing so, it aims to provide effective treatment options for patients suffering from severe lipid disorders.
The company primarily serves patients with rare diseases, a niche but critical segment of the healthcare market. These patients often have limited treatment options, making PRD Therapeutics' work highly impactful. The company also engages with healthcare providers, researchers, and pharmaceutical partners to advance its drug development efforts.
PRD Therapeutics operates on a business model that includes research and development (R&D) of new drugs, followed by clinical trials to test their safety and efficacy. Once a drug is proven effective, the company seeks regulatory approval to bring it to market. Revenue is generated through the sale of these approved drugs, as well as through partnerships and licensing agreements with larger pharmaceutical companies.
The company recently completed an $8.75 million Series A financing round, led by JAFCO and supported by new investors like JIC Venture Growth Investments, Mizuho Capital, and SMBC Venture Capital. This funding will accelerate the development of PRD001, bringing it closer to market availability.
In recognition of its innovative approach, PRD Therapeutics received the Excellence Award at the Japan Healthcare Business Contest JHeC 2024, highlighting its potential to make significant contributions to the healthcare field.
Keywords: drug discovery, lipid metabolism, rare diseases, PRD001, SOAT2 inhibitor, biopharmaceutical, HoFH, NASH, Series A financing, healthcare innovation.